Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This trial is designed to evaluate the efficacy and toxicity of Bortezomib , an inhibitor of
proteasome used in multiple myeloma, in patients with advanced Waldenström's
Macroglobulinemia disease.